Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of gecacitinib in CNL and MDS/MPN-SF3B1-T
ChiCTR2500113793Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of jaktinib in chronic neutrophilic leukemia (CNL) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Clinical Response Rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
jaktinib
03
Conditions
chronic neutrophilic leukemia (CNL)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on ChiCTR2500113793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113793.